These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12819914)

  • 1. Currently used non-specific extracellular MR contrast media.
    Bellin MF; Vasile M; Morel-Precetti S
    Eur Radiol; 2003 Dec; 13(12):2688-98. PubMed ID: 12819914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MR contrast agents, the old and the new.
    Bellin MF
    Eur J Radiol; 2006 Dec; 60(3):314-23. PubMed ID: 17005349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of magnetic resonance imaging contrast agents.
    Shellock FG; Kanal E
    J Magn Reson Imaging; 1999 Sep; 10(3):477-84. PubMed ID: 10508312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast agents used in MR imaging of the liver.
    Karabulut N; Elmas N
    Diagn Interv Radiol; 2006 Mar; 12(1):22-30. PubMed ID: 16538580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Pictorial Review of Hepatobiliary Magnetic Resonance Imaging With Hepatocyte-Specific Contrast Agents: Uses, Findings, and Pitfalls of Gadoxetate Disodium and Gadobenate Dimeglumine.
    Scali EP; Walshe T; Tiwari HA; Harris AC; Chang SD
    Can Assoc Radiol J; 2017 Aug; 68(3):293-307. PubMed ID: 28583364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonionic magnetic resonance imaging contrast agents. Clinical trial experience of safety, tolerance, and efficacy of gadodiamide injection.
    Van Wagoner M; O'Toole M; Quay SC
    Invest Radiol; 1990 Sep; 25 Suppl 1():S39-41. PubMed ID: 2283251
    [No Abstract]   [Full Text] [Related]  

  • 7. MR contrast enhancement of intracranial lesions with Gd-DTPA.
    Hesselink JR; Press GA
    Radiol Clin North Am; 1988 Jul; 26(4):873-87. PubMed ID: 3289078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents.
    Runge VM
    Invest Radiol; 2017 Jun; 52(6):317-323. PubMed ID: 28368880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of approved MR contrast media for intravenous injection.
    Runge VM
    J Magn Reson Imaging; 2000 Aug; 12(2):205-13. PubMed ID: 10931582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contrast agents in MRT. Substance, effects, pharmacology and validity].
    Reimer P; Vosshenrich R
    Radiologe; 2004 Mar; 44(3):273-83. PubMed ID: 15287365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MR diagnosis of hepatic metastases from neuroendocrine tumors versus hemangiomas: relative merits of dynamic gadolinium chelate-enhanced gradient-recalled echo and unenhanced spin-echo images.
    Soyer P; Gueye C; Somveille E; Laissy JP; Scherrer A
    AJR Am J Roentgenol; 1995 Dec; 165(6):1407-13. PubMed ID: 7484575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.
    Caravan P
    Acc Chem Res; 2009 Jul; 42(7):851-62. PubMed ID: 19222207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressing Toward a Cohesive Pediatric 18F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?
    Klenk C; Gawande R; Tran VT; Leung JT; Chi K; Owen D; Luna-Fineman S; Sakamoto KM; McMillan A; Quon A; Daldrup-Link HE
    J Nucl Med; 2016 Jan; 57(1):70-7. PubMed ID: 26471690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Signal Intensity in Globus Pallidus and Dentate Nucleus on Unenhanced T1-weighted MR Images: Evaluation of Two Linear Gadolinium-based Contrast Agents.
    Ramalho J; Castillo M; AlObaidy M; Nunes RH; Ramalho M; Dale BM; Semelka RC
    Radiology; 2015 Sep; 276(3):836-44. PubMed ID: 26079490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal handling and physiologic effects of the paramagnetic contrast medium, gadolinium-DOTA.
    Katzberg RW; Sahler LG; Duda SW; Morris TW; McKenna BA; Pabico RC; Niedrach WL; Tonetti FW
    Invest Radiol; 1991 Nov; 26 Suppl 1():S129-30; discussion S137-8. PubMed ID: 1808108
    [No Abstract]   [Full Text] [Related]  

  • 16. Advocating the Development of Next-Generation High-Relaxivity Gadolinium Chelates for Clinical Magnetic Resonance.
    Runge VM; Heverhagen JT
    Invest Radiol; 2018 Jul; 53(7):381-389. PubMed ID: 29462023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Gadolinium Retention After Serial Administrations of a Macrocyclic Gadolinium-Based Contrast Agent (Gadobutrol): A Single-Institution Experience With 189 Patients.
    Yoo RE; Sohn CH; Kang KM; Yun TJ; Choi SH; Kim JH; Park SW
    Invest Radiol; 2018 Jan; 53(1):20-25. PubMed ID: 28742734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can gadolinium be safely given in renal failure?
    Weissleder R
    AJR Am J Roentgenol; 1996 Jul; 167(1):278-9. PubMed ID: 8659405
    [No Abstract]   [Full Text] [Related]  

  • 19. Steady-state and dynamic MR angiography with MS-325: initial experience in humans.
    Grist TM; Korosec FR; Peters DC; Witte S; Walovitch RC; Dolan RP; Bridson WE; Yucel EK; Mistretta CA
    Radiology; 1998 May; 207(2):539-44. PubMed ID: 9577507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MR imaging of the gastrointestinal tract with i.v., gadolinium and diluted barium oral contrast media compared with unenhanced MR imaging and CT.
    Low RN; Francis IR
    AJR Am J Roentgenol; 1997 Oct; 169(4):1051-9. PubMed ID: 9308464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.